Ultime notizie per 60 Degrees (NASDAQ:SXTP) Azioni

60 Degrees

60 Degrees Pharmaceuticals Inc operates as a specialty pharmaceutical company with the goal of using biological science and applied research to develop and commercialize new therapies for the prevention and treatment of infectious diseases. The firm's pipeline products under development cover development programs for COVID-19, fungal, tick-borne, and other viral diseases.

Long Ideas

News

Penny Stocks

Insider Trades

Markets

Trading Ideas

Envoy Medical, Inc. - Class A Common Stock

COCH

HYLN

SXTP

Scopri le penny stock sotto i $5 in cui Hyliion e altri due titoli stanno attirando l&#39;attenzione degli insider.

Penny stock sotto i $5: Hyliion e altri 2 titoli sotto osservazione

60 Degrees Pharmaceuticals, Inc. - Common Stock

60 Degrees Pharmaceuticals Inc

60 Degrees Pharmaceuticals, Inc. - Warrant

TD Cowen analyst Jeffrey Osborne maintains Generac Hldgs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GNRC#NYSE">GNRC</a>) with a Buy and raises the price target from $172 to $183.

Price Target

Analyst Ratings

GNRC

TD Cowen Maintains Buy on Generac Hldgs, Raises Price Target to $183

UBS analyst Eliana Merle maintains Madrigal Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MDGL#NASDAQ">MDGL</a>) with a Buy and raises the price target from $411 to $441.

MDGL

UBS Maintains Buy on Madrigal Pharmaceuticals, Raises Price Target to $441

TD Cowen analyst Jeffrey Osborne maintains Itron (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ITRI#NASDAQ">ITRI</a>) with a Buy and raises the price target from $125 to $136.

ITRI

TD Cowen Maintains Buy on Itron, Raises Price Target to $136

Craig-Hallum analyst Anthony Stoss maintains Silicon Motion Technology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SIMO#NASDAQ">SIMO</a>) with a Buy and lowers the price target from $96 to $90.

SIMO

Craig-Hallum Maintains Buy on Silicon Motion Technology, Lowers Price Target to $90

On Thursday,&nbsp;Bristol Myers Squibb &amp; Co&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BMY#NYSE">BMY</a>)&nbsp;posted third-quarter revenues of $11.89 billion, beating the consensus of $11.28 billion, an increase of 8% year-over-year, or 10% when adjusted for foreign exchange impacts, primarily driven by the&nbsp;<a target="_blank" href="https://www.benzinga.com/general/biotech/24/10/41655052/bristol-myers-squibb-boosts-2024-outlook-on-strong-demand-for-blood-thinner-med-new-drugs-drive-q" rel="noreferrer noopener">Growth Portfolio and&nbsp;Eliquis</a>.
Growth Portfolio worldwide revenues increased to $5.81 billion compared to $4.95&nbsp;billion a year ago, representing growth of 18% on a reported basis or 20% when adjusted for&nbsp;foreign exchange impacts.
BMO Capital Markets appreciates a conservative approach in the neuropsych space, though it notes management&#8217;s reserved stance on revenue expectations. It highlights that significant revenue is not expected until the second half of 2025, with a gradual launch anticipated for schizophrenia treatment.
The analyst considers the potential for Alzheimer&#8217;s psychosis treatment as an added upside, likely to positively impact sentiment.
While Bristol-Myers Squibb&#8217;s recent quarterly performance showed encouraging progress in top-line growth and cost management, its true transformation will stem from its pipeline, the BMO analyst writes.
The recent approval of Cobenfy, along with newly launched growth products, could bring the momentum investors have been anticipating.
Truist analysts noted that much of the Q3 earnings call centered on KarXT (Cobenfy), a critical asset for treating schizophrenia that could drive significant revenue and support long-term growth.
Truist analyst projects global peak sales at $4.2 billion, below the $5.4 billion consensus estimate.
While business development and partnerships are crucial to diversifying the company&#8217;s portfolio and strengthening its long-term outlook, Truist emphasized that maintaining dividends and reducing debt remain top priorities.
Price Action: BMY stock is down 1.91% at $54.71 at last check Friday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/biotech/24/11/41686173/cancer-focused-essa-pharma-ends-prostate-cancer-trial-due-to-insufficient-efficacy-from-combinati" target="_blank" rel="noreferrer noopener">Cancer-Focused ESSA Pharma Ends Prostate Cancer Trial Due to Insufficient Efficacy From Combination Therapy</a></li>
</ul>
Image: Wikimedia Commons

Analyst Color

Biotech

Large Cap

Health Care

General

Bristol Myers Squibb Expects New Schizophrenia Treatment To Boost Long-Term Growth, Analysts Remain Cautious

Shares of Trump Media &amp; Technology Group Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DJT#NASDAQ">DJT</a>) are trading lower Friday amid <a href="https://www.benzinga.com/markets/equities/24/11/41677355/trump-loses-1-9b-in-net-worth-as-djt-stock-tumbles-2nd-time-this-week">continued volatility</a> leading up to the 2024 U.S. presidential election.
What To Know: With the US elections approaching, Trump Media &amp; Technology Group's stock is experiencing volatility as it is closely tied to news about former President Trump and his prospects of winning.
According to S3 Partners, DJT shares surged in October as a short squeeze forced short sellers to cover positions. S3 predicts DJT could climb to $60 if Trump wins the election, but warns it could become "worthless" if he loses. Trading in DJT has been halted several times amid rapid price movements related to election developments.
What Else: <a href="https://nypost.com/2024/11/01/business/truth-social-stock-boom-fueled-by-chatter-of-possible-sale-to-elon-musk/">Commentary from the New York Post</a> this morning speculated Elon Musk may be considering a merger or acquisition of Truth Social through X (formerly Twitter). The Post has not confirmed this speculation. 
DJT Price Action: Trump Media and Technology shares were down 11.3% at $31.34 at the time of writing, according to <a href="https://pro.benzinga.com/dashboard">Benzinga Pro.</a>
<figure class="wp-block-image size-large is-resized"><a href="https://benzinga.slack.com/archives/D072651PB4K/p1727794380964569"><img loading="lazy" decoding="async" width="1024" height="530" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/01132722/DJT-1024x530.png" alt="" class="wp-image-626033" style="width:519px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/01132722/DJT-1024x530.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/01132722/DJT-300x155.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/01132722/DJT-768x397.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/01132722/DJT.png 1480w" sizes="(max-width: 1024px) 100vw, 1024px" /></a></figure>
Read Next:
<ul>
<li><a href="https://www.benzinga.com/startups/24/11/41691861/im-not-kidding-reddit-was-amazing-jim-cramer-compares-reddit-to-google-saying-choosing-between-them">&#8216;I&#8217;m Not Kidding, Reddit Was Amazing&#8217; — Jim Cramer Compares Reddit To Google, Saying Choosing Between Them Isn&#8217;t Easy</a></li>
</ul>
Image via Wikimedia Commons.

Movers

Trump Media & Technology Shares Are Dipping Today: What's Going On

UBS analyst Stephen Ju maintains Amazon.com (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>) with a Buy and raises the price target from $223 to $230.

AMZN

UBS Maintains Buy on Amazon.com, Raises Price Target to $230

TD Cowen analyst Moshe Orenbuch maintains Credit Acceptance (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CACC#NASDAQ">CACC</a>) with a Sell and lowers the price target from $400 to $380.

CACC

TD Cowen Maintains Sell on Credit Acceptance, Lowers Price Target to $380

Roth MKM analyst Scott Stember maintains Fox Factory Hldg (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FOXF#NASDAQ">FOXF</a>) with a Neutral and lowers the price target from $45 to $36.

FOXF

Roth MKM Maintains Neutral on Fox Factory Hldg, Lowers Price Target to $36

Roth MKM analyst Chip Moore maintains Itron (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ITRI#NASDAQ">ITRI</a>) with a Buy and raises the price target from $125 to $130.

Roth MKM Maintains Buy on Itron, Raises Price Target to $130

<a href="https://www.bloomberg.com/news/articles/2024-11-01/chevron-flags-possible-us-job-cuts-in-3-billion-cost-cutting" title="https://www.bloomberg.com/news/articles/2024-11-01/chevron-flags-possible-us-job-cuts-in-3-billion-cost-cutting">https://www.bloomberg.com/news/articles/2024-11-01/chevron-flags-possible-us-job-cuts-in-3-billion-cost-cutting</a>

Reported Earlier: 'Chevron Flags Possible Job Cuts in $3 Billion Cost Plan' - Bloomberg

TD Cowen analyst Bill Katz maintains Janus Henderson Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JHG#NYSE">JHG</a>) with a Buy and raises the price target from $46 to $50.

Janus Henderson Group plc Ordinary Shares

TD Cowen Maintains Buy on Janus Henderson Group, Raises Price Target to $50

Raymond James analyst Bobby Griffin maintains Tempur Sealy Intl (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TPX#NYSE">TPX</a>) with a Strong Buy and lowers the price target from $57 to $55.

Raymond James Maintains Strong Buy on Tempur Sealy Intl, Lowers Price Target to $55

TD Cowen analyst Moshe Orenbuch maintains Navient (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NAVI#NASDAQ">NAVI</a>) with a Sell and lowers the price target from $14 to $13.

NAVI

TD Cowen Maintains Sell on Navient, Lowers Price Target to $13

Raymond James analyst Savanthi Syth maintains SkyWest (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SKYW#NASDAQ">SKYW</a>) with a Outperform and raises the price target from $100 to $114.

SKYW

Raymond James Maintains Outperform on SkyWest, Raises Price Target to $114

Raymond James analyst John Ransom maintains Service Corp Intl (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SCI#NYSE">SCI</a>) with a Outperform and raises the price target from $80 to $85.

Raymond James Maintains Outperform on Service Corp Intl, Raises Price Target to $85

Shell PLC (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SHEL#NYSE">SHEL</a>) shares are <a target="_blank" href="https://www.benzinga.com/movers" rel="noreferrer noopener">trading relatively flat on Friday.</a>
Yesterday, the company reported revenue of&nbsp;$71.09 billion, beating the&nbsp;<a target="_blank" href="https://www.benzinga.com/pressreleases/24/10/g41645206/shell-plc-3rd-quarter-2024-unaudited-results" rel="noreferrer noopener">consensus of&nbsp;$61.34 billion</a>.&nbsp;Total&nbsp;production&nbsp;at Integrated Gas fell&nbsp;4% quarter over quarter (Q/Q) to 941 kboe/d, and Upstream rose 2%&nbsp;Q/Q at&nbsp;1,811 kboe/d.&nbsp;
RBC Capital Markets analyst Biraj Borkhataria reiterated the Outperform rating on Shell, with a price forecast of 3,500 pence.
The analyst highlighted that the earnings beat was notable for being broad-based rather than reliant on a single division.
Borkhataria projects management to look through softer quarters and maintain buybacks at $3.5 billion per quarter through next year.
According to the analyst, strong performance in the LNG division and resilient upstream earnings contributed to the positive results. Additionally, net debt (excluding leases) has fallen to just under $9 billion, the lowest level in over a decade.
Also Read: <a target="_blank" href="https://www.benzinga.com/news/earnings/24/10/41652225/shells-solid-q3-performance-strong-revenue-3-5-billion-buyback-" rel="noreferrer noopener">Shell&#8217;s Solid Q3 Performance: Strong Revenue, $3.5 Billion Buyback, And Refined Capex Guidance</a>
They also mentioned that positive commentary on shareholder returns supports the stock, and Shell&#8217;s strong balance sheet offers flexibility in a potential downturn.
This positions the company to maintain share buybacks even in a weaker macro environment, and the analyst anticipates that the contrast with its peers will become more apparent by 2025.
Scotiabank Global Equity Research analyst Paul Y. Cheng reiterated the Outperform rating on Shell, <a target="_blank" href="https://www.benzinga.com/quote/SHEL/analyst-ratings" rel="noreferrer noopener">with a price forecast of $80.</a>
The earnings beat was broad-based, with Shell exceeding consensus estimates in all key segments, including Upstream, Integrated Gas, Marketing, and Chemicals &amp; Products.
The only exception was the smaller Renewables and Energy Solutions division, which slightly fell short of the market&#8217;s expectations.
The analyst noted that Shell repurchased $3.5 billion in shares during the third quarter, meeting expectations.
Cheng also indicated that the company is likely to maintain its current buyback pace despite a less favorable outlook for commodity prices.
Price Action: SHEL shares are trading lower by 0.06% to $67.51 at last check Friday.
Image by siam.pukkato via Shutterstock
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/equities/24/10/41497086/shell-fuels-the-future-new-deal-with-ferrari-and-power-plant-acquisition-on-the-horizon" target="_blank" rel="noreferrer noopener">Shell Fuels The Future: New Deal with Ferrari And Power Plant Acquisition On The Horizon</a></li>
</ul>

Equities

Reiteration

SHEL

Shell Reports Strong Q3: Analysts Highlight Robust Buybacks Amid Market Challenges

Raymond James analyst Joseph Altobello maintains Patrick Industries (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PATK#NASDAQ">PATK</a>) with a Outperform and lowers the price target from $160 to $136.

PATK

Raymond James Maintains Outperform on Patrick Industries, Lowers Price Target to $136

Maxim Group analyst Tom Forte maintains Apple (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>) with a Hold and raises the price target from $203 to $215.

AAPL

Maxim Group Maintains Hold on Apple, Raises Price Target to $215

Raymond James analyst Adam Tindle maintains Atlassian (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TEAM#NASDAQ">TEAM</a>) with a Outperform and raises the price target from $200 to $250.

TEAM

Raymond James Maintains Outperform on Atlassian, Raises Price Target to $250

In a report released today, Edward White from H.C. Wainwright maintained a Hold rating on 60 Degrees Pharmaceuticals, Inc. (SXTP – Research Report)...

H.C. Wainwright Keeps Their Hold Rating on 60 Degrees Pharmaceuticals, Inc. (SXTP)

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
60 Degrees Pharmaceuticals (NASDAQ:<a href="https://investorplace.com/stock-quotes/sxtp-stock-quote/">SXTP</a>) stock is gaining on Monday after the specialty pharmaceutical company <a href="https://finance.yahoo.com/news/60-degrees-pharma-provides-university-131200159.html">announced an agreement</a> with the University of Kentucky.



This agreement will have the University of Kentucky conducting a Phase IIb clinical trial of SJ733. This is a drug candidate in development by 60 Degrees Pharmaceuticals for the treatment of vivax malaria.



This study will cover the use of SJ733 alongside tafenoquine to treat vivax malaria. The information from this study will also be applied to 60 Degrees Pharmaceuticals New Drug Application (NDA) for the drug.



Dr. R. Kip Guy, the principal investigator of the study, said the following about it:




&ldquo;Innovations in treating P. vivax malaria, which infects an estimated 14 million people a year, have been limited in recent decades. The upcoming study of SJ733 combined with tafenoquine has the potential to pave the way for very meaningful improvement in malaria treatment around the world.&rdquo;




<h2>What This Means for SXTP Stock</h2>



This new clinical trial news has SXTP stock heading higher on Monday with heavy trading of the shares. That has more than 11.9 million shares changing hands as of this writing. To put that in perspective, the company&rsquo;s daily average trading volume is about 448,000 shares.



SXTP stock is up 28.9% as of Monday afternoon.



There are even more stock market stories traders are going to want to read about below!



We have all of the hottest stock market news ready to go on Monday! A few examples include what&rsquo;s going on with shares of Draganfly&nbsp;(NASDAQ:<a href="https://investorplace.com/stock-quotes/dpro-stock-quote/">DPRO</a>), KeyBank (NYSE:<a href="https://investorplace.com/stock-quotes/key-stock-quote/">KEY</a>) and Archer Aviation&nbsp;(NYSE:<a href="https://investorplace.com/stock-quotes/achr-stock-quote/">ACHR</a>) stock today. All of this news is available at the following links!



<h2>More Monday Stock Market News</h2>



<ul><li><a href="https://investorplace.com/2024/08/why-is-draganfly-dpro-stock-up-37-today/">Why Is Draganfly (DPRO) Stock Up 37% Today?</a></li>



<li><a href="https://investorplace.com/2024/08/key-stock-surge-alert-whats-going-on-with-keycorp-shares-today/">KEY Stock Surge Alert: What&rsquo;s Going On With KeyCorp Shares Today?</a></li>



<li><a href="https://investorplace.com/2024/08/achr-stock-3-things-for-investors-to-know-about-the-370-million-stellantis-deal/">ACHR Stock: 3 Things for Investors to Know About the $370 Million Stellantis Deal</a></li>
</ul>On Penny Stocks and Low-Volume Stocks:&#8239;With only the rarest exceptions, InvestorPlace does not publish commentary about companies that have a market cap of less than $100 million or trade less than 100,000 shares each day. That&rsquo;s because these &ldquo;penny stocks&rdquo; are frequently the playground for scam artists and market manipulators. If we ever do publish commentary on a low-volume stock that may be affected by our commentary, we demand that&#8239;InvestorPlace.com&rsquo;s writers disclose this fact and warn readers of the risks.



Read More:&#8239;Penny Stocks &mdash;&nbsp;<a href="https://investorplace.com/2014/05/fraud-penny-stocks-scams/" target="_blank">How to Profit Without Getting Scammed</a>



On the date of publication, William White did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the&nbsp;InvestorPlace.com&nbsp;<a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/" target="_blank">Publishing Guidelines</a>.



On the date of publication, the responsible editor did not have (either directly or indirectly) any positions in the securities mentioned in this article.
<h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget AI... THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul>The post <a href="https://investorplace.com/2024/08/why-is-60-degrees-pharmaceuticals-sxtp-stock-up-29-today/">Why Is 60 Degrees Pharmaceuticals (SXTP) Stock Up 29% Today?</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

Why Is 60 Degrees Pharmaceuticals (SXTP) Stock Up 29% Today?

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
60 Degrees (NASDAQ:<a href="https://investorplace.com/stock-quotes/sxtp-stock-quote/">SXTP</a>) just reported results for the second quarter of 2024.<ul><li>60 Degrees reported earnings per share of -$4.23. This was below the analyst estimate for EPS of -23 cents.</li><li>The company reported revenue of $124,972.</li><li>This was 37.51% worse than the analyst estimate for revenue of $200,000.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget AI... THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul>The post <a href="https://investorplace.com/earning-results/2024/08/sxtp-stock-earnings-60-degrees-for-q2-of-2024/">SXTP Stock Earnings: 60 Degrees Misses EPS, Misses Revenue for Q2 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

SXTP Stock Earnings: 60 Degrees Misses EPS, Misses Revenue for Q2 2024

H.C. Wainwright Sticks to Their Hold Rating for 60 Degrees Pharmaceuticals, Inc. (SXTP)

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Outlook Therapeutics (OTLK – Research Report), 60 ...

Analysts Offer Insights on Healthcare Companies: Outlook Therapeutics (OTLK), 60 Degrees Pharmaceuticals, Inc. (SXTP) and Gritstone Oncology (GRTS)

60 Degrees Pharmaceuticals GAAP EPS of -$4.23

Earnings week ahead: Zoom, Lowe's, Target, Baidu, XPeng, Zim Integrated and more

60 Degrees Pharmaceuticals to raise $4M via private placement; shares fall

H.C. Wainwright analyst Edward White maintained a Hold rating on 60 Degrees Pharmaceuticals, Inc. (SXTP – Research Report) today. The company's sha...

H.C. Wainwright Reaffirms Their Hold Rating on 60 Degrees Pharmaceuticals, Inc. (SXTP)

Warning: SXTP is at high risk of performing badly

ASND

AYRO

BIDU

BILI

BTBT

CARA

CATO

COTY

CSIQ

CTXR

ESTC

FORD

FUTU

GGAL

GRTS

IMMR

INTU

JKHY

KEYS

MBRX

MMAT

NNDM

NNOX

NTES

OTLK

PANW

PTON

ROST

SEEL

SNOW

SNPS

URBN

VIPS

WDAY

WKHS

WOLF

XPEV

Press Releases

60 Degrees Pharma Announces IRB Approval of Clinical Study of Tafenoquine for Treatment of Babesiosis in Immunocompromised Patients with Persistent Babesia microti Despite Prior Treatment

Comments

60 Degrees

Notizie

Ultime notizie per 60 Degrees (NASDAQ:SXTP) Azioni

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO